ArticleJournal of cardiothoracic surgery2026
Serum long non-coding RNA SNHG9 as a diagnostic biomarker for acute coronary syndrome and a predictor of prognosis following percutaneous coronary intervention: a clinical evaluation.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the change of lifestyle and the aging of the population, the incidence of Acute coronary syndrome (ACS) is increasing and showing a trend of younger patients. Therefore, the study of risk factors for ACS has important clinical implications for the diagnosis and prognosis of patients. The purpose of this study was to explore the role of long non-coding RNA (lncRNA) SNHG9 in the diagnosis and prognosis of ACS, with a view to developing new biomarkers for the diagnosis and prognosis of ACS.
methodsA total of 130 ACS patients and 99 healthy subjects were included in this study, and their serum SNHG9 levels were measured by RT-qPCR. The diagnostic value of SNHG9 in ACS was evaluated by ROC curve and binary Logistic analysis. Risk factors for major adverse cardiovascular events (MACE) in patients with ACS were analyzed using Kaplan-Meier curves and multivariate Cox regression. Correlation of SNHG9 levels with clinical indicators was analyzed using Pearson and Spearman methods.
resultsSNHG9 was highly expressed in ACS patients compared to healthy subjects. Logistic analysis and ROC results showed high diagnostic accuracy of SNHG9 in ACS patients (OR = 7.106, P < 0.001; AUC = 0.929). Furthermore, SNHG9 expression was upregulated in the MACE events group compared to the group without MACE events. Kaplan-Meier curves indicated lower survival in ACS patients with high SNHG9 expression (P = 0.002). Cox results showed that SNHG9 is a risk factor for MACE events in ACS patients after treatment. Besides, SNHG9 was positively and significantly correlated with cTnI, NT-proBNP, hs-CRP, Gensini score, and the number of diseased vessels.
conclusionsSNHG9 has high predictive value for the diagnosis and prognosis of ACS patients, which may become a biomarker for clinical diagnosis and prediction of survival outcome in ACS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.